shards of a disc in the air
Biotech

Disc's rare disease drug hit by FDA rejection

Disc’s bitopertin had hit the primary endpoint in what the FDA agreed was an adequate and well-controlled trial.
wheel

Biohaven CEO calls recent FDA decisions 'a systemic problem'

Feb 13, 2026 4:14pm
How AI Is reshaping clinical trials and market access

How AI Is reshaping clinical trials and market access

Feb 9, 2026 8:00am
Bahija Jallal

After R&D head exits, Immunocore CEO pairs ambition with caution

Feb 13, 2026 12:44pm
Article Primary Image 1jpg

The Data Multiplier Effect: The 4 Forces Changing Biometrics

Feb 9, 2026 8:00am
Wall Street IPO

Why biotech IPOs are back for 2026

Feb 13, 2026 3:30am
More News

What were the biggest clinical trial flops of 2025?

Feb 13, 2026 11:47am
Fierce Pharma

Vaccine makers facing increased volatility, uncertainty at FDA

Feb 13, 2026 11:12am

Moderna R&D spend shrunk 31% in 2025 amid major pipeline reorg

Feb 13, 2026 10:10am

Fierce Biotech Layoff Tracker 2026: Seres, ARPA-H & more

Feb 13, 2026 9:00am